Lack of defect in oxidative hydroxylation of debrisoquine in a patient with halothane hepatitis.
Toutoungi
M
M
Department of Clinical Psychopharmacology, University of Geneva, Chene Bourg, Switzerland.
Magnenat
D
D
D000328:Adult; D056486:Chemical and Drug Induced Liver Injury / Q000378:metabolism*; D019389:Cytochrome P-450 CYP2D6; D003577:Cytochrome P-450 Enzyme System / Q000378:metabolism; D003647:Debrisoquin / Q000378:metabolism*; D005260:Female; D006221:Halothane / Q000009:adverse effects*; D006801:Humans; D006900:Hydroxylation; D007546:Isoquinolines / Q000378:metabolism*; D006899:Mixed Function Oxygenases / Q000378:metabolism; D010084:Oxidation-Reduction; D010641:Phenotype
D007546:Isoquinolines; D003577:Cytochrome P-450 Enzyme System; D006899:Mixed Function Oxygenases; D019389:Cytochrome P-450 CYP2D6; D006221:Halothane; D003647:Debrisoquin